Yatharth Hospital Report Download ##HOT##

Yatharth Hospital intends to use the net proceeds to pay off or advance debt, Fund capital expenditure expenses for the company's two hospitals, Noida Hospital and Greater Noida Hospital, as well as for the hospitals run by the company's subsidiaries AKS and Ramraja. Additionally, fund inorganic growth initiatives through acquisitions and general corporate purposes.

Canara Bank Securities According to the brokerage's analysis, hospitals must provide pricing that are 20% less expensive than those of their competitors in order to establish their reputation. They have aspirations to expand in close proximity to Delhi and sections of Uttar Pradesh. They have claimed strong financial performance across the board. In terms of CAGR over a two-year period, revenue and profit after tax have risen by 51% and 83%, respectively.

Yatharth Hospital Report Download

DOWNLOAD 🔥 https://ssurll.com/2y7OwX 🔥

This issue is available at P/EPS of 29.73x, which is lower as compared to peer competitors. This cannot be apple-to-apple comparison, as this hospital is mainly concentrated in Delhi and they are emerging as multi speciality hospital among renowned peers. They have recently introduced kidney transplantation, bone marrow transplantation and oncology department. These speciality services will add cost to the hospital in medium to long term, hence margins could see pressure. Majorly, their revenue contributes majorly 34% from government deals which can stretch the debtor days and margin as well. Hence, we recommend to subscribe the issue for Listing gains," added the brokerage.

The company operates in highly competitive segment. Their high fixed costs may negatively affect their profitability. Additionally, unfavorable pricing on medical supplies or the inability to pass on cost increases to payers could further impact their profitability. Keeping in mind the pros & cons of the company, cash surplus investors can invest in the issue, " said the brokerage in its report.

Going forward, this is anticipated to get better, benefitting the company's expansion goals. Their most recent purchase of the Jhansi-Orchha hospital is intended to help them continue to expand into new areas and strengthen their position in the local healthcare industry.

We assign 'Subscribe' rating to this IPO as the company is one of the leading super-specialty hospitals in Delhi NCR; this institution boasts a diverse range of specialties and payer mix, demonstrating a track record of consistent and stable operating and financial performance, with sustained growth. Also it is available at a reasonable valuation compared to its peers," the brokerage said in its report.

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to: -businesses/ratings/regulatory-disclosures/highlighted-policies.html.

The current subscription data is updated in report by the total number of offering compare with total shares bid in each category for Yatharth Hospital IPO. This information has been updated every 10 mins when IPO bidding is open. Numbers are calculated from both NSE and BSE data.

Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospital chain. Yatharth Hospital operates through its super specialty hospitals. These hospitals are situated in Delhi NCR, i.e., at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. The hospital located in Noida Extension Hospital has 450 beds and is one of the largest hospitals in the area.

Yatharth Hospital and Trauma Care Services provide patients with various Amenities and facilities. All of their hospitals are accredited by the NABH. And the ones located at Greater Noida and Noida Extension are accredited by NABL. The hospitals comply with all necessary international quality standards to ensure safety and recovery of the patients.

[Dilip Davda] The company has a 1405-bed capacity four hospitals chain in the northern region and is one of the leading healthcare service providers. Based on its current financial status, the issue appears fully priced but is poised for bright prospects ahead. Investors may consider parking funds for the medium to long-term rewards. Read detail review...

Bangalore, August 18, 2023: Yatharth Hospital and Trauma Care Services Ltd, one of the leading private super specialty hospitals in Delhi NCR, announced its financial results today for the quarter ended June 30, 2023. 006ab0faaa